Company Overview

GelStat Corporation is a publicly traded company trading under the symbol (“GSAC”) that is engaged in research, development, marketing and branding of innovative over-the-counter (OTC) consumer healthcare products addressing very large markets. The Company’s strategy is to expand through organic growth and strategic acquisitions.

GSAC Engineering is our division dedicated to developing innovative technologies for clean energy and industrial security. Our vision is to create a more sustainable and secure future for our customers and society. We are committed to integrating STEM (science, technology, engineering and math) into our processes and products, as we believe that STEM skills are essential for solving complex challenges and creating value in the 21st century.

Our clean energy technologies include converting plastic waste into crude oil, which can reduce greenhouse gas emissions and landfill space. These technologies can help improve our quality of life by reducing air, water, and land pollution, mitigating energy dependence, and creating economic opportunities. According to Zion Market Research, the global market for plastic waste to oil was valued at approximately USD 48.2 Million in 2019, and is expected to grow at a CAGR of around 9.4% between 2020 and 2026.

Our industrial security solutions include CCTV cameras, access control systems, communication devices, and wearable devices that can protect our clients’ assets and operations from threats such as theft, vandalism, sabotage, cyberattacks and natural disasters. We also offer remote video surveillance services that can reduce costs and increase efficiency. We use advanced AI algorithms to analyze data and provide real-time insights for optimal response. Moreover, we are developing infrastructure that will enable communications designed to monitor safety and wellbeing in locations where radio and cellphone signals are not available or useful. According to Global Market Insights, the global market for industrial control systems security surpassed USD 5 billion in 2022 and is expected to grow at a CAGR of 20% from 2023 to 2032.

GelStat’s products have innovative formulations combined with uniquely advantageous delivery systems that provide consumers with clinically proven products that have improved efficacy, safety and convenience. In line with this strategy, two clinical trials have been conducted on GelStat™ Migraine, both yielding positive results. The Company is presently targeting the following markets:

GelStat Migraine - Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, expects the market for migraine therapies to grow from $3.3 billion in 2011 to $5.8 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

GelStat Sleep - The total over-the-counter market for sleep aids alone reached $604 million in 2008, an increase of 9 percent over 2007, according to Packaged Facts, a division of Rockville, Md.-based Market Research Group.

Joint Pain Products- GBI Research analysis shows that the global arthritis therapeutics market was estimated at $20.6 billion in 2010, during the forecast period the market grow at a Compound Annual Growth Rate (CAGR) of 7.2% between 2010 and 2018 to a market valued at $38 billion.